Therefore, determination of galectin-3 blood levels, as a marker of fibrosis, may be used for indirect assessment of fibrosis severity and the risk of AF in patients, especially those with metabolic syndrome [41]. This evidence concerns the gene LGALS3 and atrial fibrillation.